Background: One of the most common cancer in males
was lung cancer and non-small cell variant in
worldwide. The main treatment was is surgery and
chemotherapy and/or radiotherapy in non-small cell
lung cancer (NSCLC). Five-year survival was 15% for all
stages of NSCLC. Advanced stage patients of NSCLC were
remain without treatment because treatment related
high toxicity rates. Therefore low toxic treatments were
warranted in advanced stages of NSCLC especially with
comorbid disorders. The effect of daily low dose cisplatin
concurrently with radiation therapy was determined
with evaluating of literature in advanced NSCLC
patients with poor performance status.